1Fischer AH,Taysavang P,Jhiang SM.Nuclear envelope irregularity is induced by RET/PTC during interphase[J].Am J Pathol,2003,163(13):1091-1100.
2Puxeddu E,Moretti S,Giannieo A,et al.RET/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas[J].Eur J Endocrinol,2003,148(2):505-513.
3Liu RT,HouCY,You HL,et al.Selectiveoccurrence of ras mutations in Benign and malignant thyroid follicular neoplasms in Taiwan[J].Thyroid,2004,14(3):616-621.
5Namba H,Nakashima M,Hayashida N,et al.Clinical implication of hot spot BRAF mutation,V599E,in papillary thyroid cancers[J].J Clin Endocinol Metab,2003,88(21):4393-4397.
6Xu X,Quiros RM,Gattuso P,et al.Highprevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines[J].Can Cer Res,2003,63(15):4561-4567.
7Begum S,Rosenbaum E,Henrique R,et al.BRAF mutations in an aplastic thyroid carcinoma:implications for tumor origin,diagnosis and treatment[J].Mod Pathol,2004,17(8):1359-1363.
8Kumagai A,Namba H,Saenko VA,et al.Low frequency of BRAF T1796A mutations in childhood thyroid carcinomas[J].J Clin Endocrinol Metab,2004,89(15):4280-4284.
9Namba H,Nakashima M,Hayashida N,et al.Clinical implication of hot spot BRAF mutation,V599E,in papillary thyroid cancers[J].J Clin Endocrinol Metab,2003,88(21):4393-4397.
10Wasenius VM,Hemmer S,Kettunen E,et al.Hepatocyte growth factor receptor,matrix metalloproteinase211,tissue inhibitor of metallop roteinase21,and fibronectin are upregulated in papillary thyroidcarcinoma:ac DNA and tissue microarray study[J].Clin Cancer Res,2003,9(1):68-75.
